Ivis 200

Manufactured by PerkinElmer

Sourced in United States

The IVIS 200 is an in vivo imaging system designed for preclinical research. It allows for non-invasive, real-time visualization and quantification of bioluminescent and fluorescent signals in small animal models. The system utilizes a highly sensitive charge-coupled device (CCD) camera to capture images and data, which can be used to study a variety of biological processes, including gene expression, cell trafficking, and tumor growth.

Automatically generated - may contain errors

Lab products found in correlation

Living image software, by PerkinElmer (10 mentions) D luciferin, by PerkinElmer (5 mentions) Living image 3, by PerkinElmer (5 mentions) D luciferin, by GoldBio (4 mentions) Ivis spectrum, by PerkinElmer (3 mentions) Living image, by PerkinElmer (3 mentions) D luciferin potassium salt, by GoldBio (2 mentions) Living image 4, by PerkinElmer (2 mentions) Livingimage software 3, by PerkinElmer (1 mentions) Ivis 50, by PerkinElmer (1 mentions) Male athymic nude mice, by Taconic Biosciences (1 mentions) Avidin biotin peroxidase complex kit, by Vector Laboratories (1 mentions) Luciferin, by Thermo Fisher Scientific (1 mentions) Blasticidin, by Thermo Fisher Scientific (1 mentions) Luciferin, by PerkinElmer (1 mentions) Luciferin, by Promega (1 mentions) Inveon small animal pet ct, by Siemens (1 mentions) Inveon research workplace software, by Siemens (1 mentions) Hygromycin, by Thermo Fisher Scientific (1 mentions) Jetpei macrophage, by Polyplus Transfection (1 mentions)

Close spelling variants of this product

IVIS-200 small animal imager AXENOGEN IVIS 200 IVIS 200 station IVIS 200 imaging system IVIS 200 Spectrum Imaging System IVIS-200 bioluminescence imaging system Xenogen IVIS-200 Spectrum camera Xenogen-IVIS 200 in vivo Imaging System IVIS 200 optical imaging system Xenogen IVIS Imaging system 200 series

61 protocols using ivis 200

In Vitro and In Vivo Luciferase Assay for Gene Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols

In vitro luciferase assay was performed by cell transfection. Briefly, Hela cells were plated at 1 × 10⁵/well in 96well plate and then transfected with equimolar concentrations of DNA plasmid or DNA amplicon (1 and 0.3 μg). After 24 h, luciferase expression signal was measured by Imaging at an IVIS 200 imaging device (Perkin Elmer, USA).
In order to assess luciferase expression in vivo, female BALB/c mice (5 mice/group) were anesthetized using 97% oxygen and 3% isoflurane (Isoba, UK) then injected by EP in quadriceps muscle with a DNA plasmid encoding Luciferase (pcDNA3-Hygro-Luc at 1 μg/mouse) or equimolar concentrations of DNA amplicon. Imaging was performed under gas anesthesia at IVIS 200 imaging system at 24 h, 48 h and one week after injection, 8 min after injecting subcutaneously a luciferin substrate solution (15 mg/ml, Perkin Elmer) at 10μl/g of body weight.

Conforti A., Salvatori E., Lione L., Compagnone M., Pinto E., Shorrock C., Hayward J.A., Sun Y., Liang B.M., Palombo F., Viscount B, & Aurisicchio L. (2022). Linear DNA amplicons as a novel cancer vaccine strategy. Journal of Experimental & Clinical Cancer Research : CR, 41, 195.

+ Open protocol

+ Expand

In vivo Biodistribution of DiD-Loaded Nanoparticles

Check if the same lab product or an alternative is used in the 5 most similar protocols

Nude mice bearing human SKOV3 ovarian cancer tumor (approximately 500 mm³) were randomized into 2 groups (3 mice per group). DiD (a hydro-phobic near-infrared (NIR) cyanine dye) was encapsulated in each nanocarrier (together with PTX and CDDP) at a ratio of 2:1:0.1 (CDDP/PTX/DiD by weight) using the same method as described above. The particle size was measured by DLS analysis. 100 μL of TM_{(DiD-PTX-CDDP)} solution was filtered with a 0.22 μm filter to sterilize solution before injection. At the same time, same amount of DiD in DMSO solution was diluted with PBS right before I.V. injection. The fluorescent DiD co-loaded TM with equivalent dose of 6 mg/kg CDDP were injected into nude mice bearing SKOV-3 tumor xenograft via tail vein. Mice were anesthetized via isoflurane and optically imaged at different time points (1 h, 2 h, 4 h, 8 h, 24 h, 48 h and 72 h) using an IVIS 200 (PerkinElmer) with the (excitation/ emission 625/700 nm). At the end of the experiments, the animals were sacri-ficed and all the major organs as well as tumors were excised for ex vivo imaging to determine the in vivo biodistribution of nanoparticles. The associated fluorescence intensities were determined by Living Image software (Caliper Life Sciences) using operator-defined regions of interest (ROI) measurements.

Cai L., Xu G., Shi C., Guo D., Wang X, & Luo J. (2014). Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials, 37, 456-468.

+ Open protocol

+ Expand

Bioluminescence Imaging of Injected Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Bioluminescent signal intensity of injected cells was determined six
hours after intrathymic injection. Fifteen minutes after intraperitoneal
injection of 3 mg/mouse D-Luciferin (Goldbio, St. Louis, MO) mice were
anesthetized and placed into the light tight chamber of an IVIS 200
bioluminescence imaging system (PerkinElmer, Melville, NY). Grayscale
photographic images of the mice were acquired first and then a low-level
bioluminescent signal was recorded. Pseudo-color images showing the whole body
distribution of bioluminescent signal intensity (photons/s) were superimposed on
the grayscale photographs.

Tuckett A.Z., Zakrzewski J.L., Li D., van den Brink M.R, & Thornton R.H. (2015). Free-hand ultrasound guidance permits safe and efficient minimally invasive intrathymic injections in both young and aged mice. Ultrasound in medicine & biology, 41(4), 1105-1111.

+ Open protocol

+ Expand

Xenograft Tumor Initiation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

SUM159-Luc cells were generated by stable transfection with firefly luciferase in a pWZL-Hygro vector (kindly provided by Dr. Maureen Murphy, Wistar Institute), followed by stable transduction with either empty vector or Flag-tagged OGT lentivirus. Cells were injected into cleared inguinal mammary fat pads of 4–6 weeks old female NOD/SCID mice. Mice were weighed, palpated and imaged weekly for bioluminescence, after intraperitoneal injection with 200 ul of D-Luciferin (20mg/ml: Perkin Elmer) on the IVIS 200. Tumors were measured using digital calipers and tumor volume was calculated using the formula (LxW²⁾/2. Extreme limiting dilution analysis (ELDA) (21 (link)) was used to calculate tumor initiating cell (TIC) frequency. Mouse experiments were performed with the approval of Institutional Animal Care and Use Committee.

Akella N.M., Le Minh G., Ciraku L., Mukherjee A., Bacigalupa Z.A., Mukhopadhyay D., Sodi V.L, & Reginato M.J. (2020). O-GlcNAc Transferase Regulates Cancer Stem-like Potential of Breast Cancer Cells. Molecular cancer research : MCR, 18(4), 585-598.

+ Open protocol

+ Expand

In Vivo Bioluminescent Imaging of FLG-luc2p Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

FLG-luc2p^+/− and FLG-luc2p^−/− (WT; wild type) mice (6–12 weeks old) were housed and used for these studies following the husbandry and experimental guidelines defined by the UK animal welfare act. In vivo live-animal imaging of FLG-luc2p^+/− mice was performed as previously described [14] (link), using the Xenogen IVIS 200 imaging system (PerkinElmer, Waltham, MA). Unless otherwise stated, all images were captured with 1 second (s) exposures. The resulting light emission was quantified using LivingImage software 3.0 (PerkinElmer). %L/R ratios were calculated by dividing left paw luciferase light emission (LLE) by right paw LLE. Baseline luciferase bioluminescent activity was defined for each experimental animal by monitoring hindpaw luciferase activity at 24 hour (h) intervals for 5–6 days prior to treatment.

Hegde V., Hickerson R.P., Nainamalai S., Campbell P.A., Smith F.J., McLean W.H, & Leslie Pedrioli D.M. (2014). In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation. Journal of Controlled Release, 196, 355-362.

+ Open protocol

+ Expand

In-vivo Fluorescence and Luminescence Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fluorescence data were obtained with the Maestro™ in-vivo fluorescence imaging system (Cambridge Research & Instrumentation) using 480 nm excitation and 515 emission filters to discriminate eGFP. Luminescence data were acquired with the IVIS 200® (Perkin Elmer) imaging platform.

Preston Campbell J., Mulcrone P., Masood S.K., Karolak M., Merkel A., Hebron K., Zijlstra A., Sterling J, & Elefteriou F. (2015). TRIzol and Alu qPCR-based quantification of metastatic seeding within the skeleton. Scientific Reports, 5, 12635.

+ Open protocol

+ Expand

Biopsy-Based Assessment of Mucosa Inflammation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Two biopsies from inflamed and normal mucosa as evaluated endoscopically were taken from each patient, placed immediately in PBS, and transported on ice to the laboratory. A third biopsy from each site was sent to the clinical pathology laboratory for routine histopathology evaluation. The adhesion test was performed within 4 hours of the biopsy as follows. Two hundred microliters of (DiD + Dex)-loaded 4% IT-hydrogel was suspended in 6 ml of PBS. Individual specimens were incubated in 0.5 ml of the gel suspension for 30 min at 37°C with gentle shaking. After washing with PBS (3×), the samples were placed on a black plastic sheet and imaged using an IVIS fluorescence imager (IVIS 200, PerkinElmer). Fluorescence signal intensity was quantified using the Living Image software (version 4.3.1, PerkinElmer). The specimens were subsequently air-dried and weighed to determine the weight-normalized fluorescence signal intensity. Specimens from 11 patients (table S1) were assayed. For inclusion in the analysis (Fig. 6), we required that endoscopy and histopathology reports were concordant for either “normal” or “inflamed” mucosa; for this reason, four patients were excluded; a fifth patient was excluded because the inflamed specimen was derived from the appendiceal orifice (table S1).

Zhang S., Ermann J., Succi M.D., Zhou A., Hamilton M.J., Cao B., Korzenik J.R., Glickman J.N., Vemula P.K., Glimcher L.H., Traverso G., Langer R, & Karp J.M. (2015). An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease. Science translational medicine, 7(300), 300ra128.

+ Open protocol

+ Expand

Bioluminescence Imaging and Serum Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were i.p. injected with 150 mg/kg D-luciferin potassium salt (Gold Biotechnology, St. Louis, MO, USA). After D-luciferin injection, bioluminescence was monitored using a bioimaging system (IVIS 200, Perkin Elmer, Santa Clara, CA, USA). Signals were quantified using Living Image 3.2 software (Perkin Elmer). After termination of the experiment on day 3, blood samples were collected from the vena cava. Alanine aminotransferase (ALT), alkaline phosphatase (ALP), and direct/total bilirubin levels in serum samples were analyzed as indicated by the manufacturer (Abbott Alinity C System, Abbot Laboratories, Chicago, IL, USA).

Nicolle L., Casper J., Willimann M., Journot C.M., Detampel P., Einfalt T., Grisch-Chan H.M., Thöny B., Gerber-Lemaire S, & Huwyler J. (2021). Development of Covalent Chitosan-Polyethylenimine Derivatives as Gene Delivery Vehicle: Synthesis, Characterization, and Evaluation. International Journal of Molecular Sciences, 22(8), 3828.

+ Open protocol

+ Expand

In Vivo Biodistribution Imaging of DiR

Check if the same lab product or an alternative is used in the 5 most similar protocols

A549 cell suspension was inoculated into nude mice via a hypodermic injection, and the mice were divided into two groups (n=3) when the tumor volume reached ∼150 mm³. The mice were then administered DiR or DiR mixed micelles via tail vein injections for imaging study, anesthetized via isoflurane, and evaluated at 1, 2, 4, 8, 12, and 24 h using the IVIS 200 imaging system (PerkinElmer, Hopkinton, MA, USA) at an excitation/emission wavelength of 625/700 nm, respectively. The exposure time was 30 s per image. After in vivo imaging, the major tissues were obtained to determine the associated fluorescence intensities for ex vivo imaging.

Zhang Y., Tong D., Che D., Pei B., Xia X., Yuan G, & Jin X. (2017). Ascorbyl palmitate/d-α-tocopheryl polyethylene glycol 1000 succinate monoester mixed micelles for prolonged circulation and targeted delivery of compound K for antilung cancer therapy in vitro and in vivo. International Journal of Nanomedicine, 12, 605-614.

+ Open protocol

+ Expand

Bioluminescence Imaging Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Optical BLI was performed 15-25 minutes after d-luciferin IP injection (400 mg/kg; PerkinElmer, MA, USA) with 3-5 minute acquisition scans on a charge-coupled device camera (IVIS 200; PerkinElmer). Peak signal from a fixed region of interest was evaluated with Living Image 3.2 software (PerkinElmer). For in vitro BLI, luciferin (16.6 mg/ml) was mixed with cell media in the tissue culture dish (10 minutes before imaging) and imaged.

Mahmoudi M., Tachibana A., Goldstone A.B., Woo Y.J., Chakraborty P., Lee K.R., Foote C.S., Piecewicz S., Barrozo J.C., Wakeel A., Rice B.W., Bell III C.B, & Yang P.C. (2016). Novel MRI Contrast Agent from Magnetotactic Bacteria Enables In Vivo Tracking of iPSC-derived Cardiomyocytes. Scientific Reports, 6, 26960.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!